Takeda Pharmaceutical (TAK) Receivables Refunds: 2018-2025
- Takeda Pharmaceutical's Receivables Refunds fell 47.49% to $103.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $103.5 million, marking a year-over-year decrease of 47.49%. This contributed to the annual value of $103.7 million for FY2025, which is 48.82% down from last year.
- Latest data reveals that Takeda Pharmaceutical reported Receivables Refunds of $103.5 million as of Q1 2025, which was down 47.49% from $197.1 million recorded in Q1 2024.
- Takeda Pharmaceutical's 5-year Receivables Refunds high stood at $279.9 million for Q1 2021, and its period low was $103.5 million during Q1 2025.
- Over the past 3 years, Takeda Pharmaceutical's median Receivables Refunds value was $197.1 million (recorded in 2024), while the average stood at $181.5 million.
- Per our database at Business Quant, Takeda Pharmaceutical's Receivables Refunds climbed by 9.15% in 2021 and then plummeted by 47.49% in 2025.
- Quarterly analysis of 5 years shows Takeda Pharmaceutical's Receivables Refunds stood at $279.9 million in 2021, then declined by 14.73% to $238.6 million in 2022, then grew by 2.21% to $243.9 million in 2023, then decreased by 19.20% to $197.1 million in 2024, then slumped by 47.49% to $103.5 million in 2025.
- Its Receivables Refunds was $103.5 million in Q1 2025, compared to $197.1 million in Q1 2024 and $243.9 million in Q1 2023.
